Machine learning identifies candidates for drug repurposing in Alzheimer’s disease

Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. We prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Steve, Hug, Clemens, Todorov, Petar, Moret, Nienke, Boswell, Sarah A., Evans, Kyle, Zhou, George, Johnson, Nathan T., Hyman, Bradley T., Sorger, Peter K., Albers, Mark W., Sokolov, Artem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884393/
https://www.ncbi.nlm.nih.gov/pubmed/33589615
http://dx.doi.org/10.1038/s41467-021-21330-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884393/
https://www.ncbi.nlm.nih.gov/pubmed/33589615
http://dx.doi.org/10.1038/s41467-021-21330-0

Ejemplares similares